Kidney Cancer
If PDT can treat tumours within the prostate and pancreas, there is no logical reason why the kidneys shouldn’t also be a target. It is a solid organ, and the area of cancer will be reasonably well-defined.
The main advantage of PDT will be that once the PDT process has destroyed the tumour, then new and healthy cells will grow to replace the cancerous ones destroyed.
The body’s own internal ‘mapping programme’ will create the new cells.
It may become rather repetitive to read that we need funding and the human resources to run such a trial programme. But we do, and finding the right team is a task we have already started.
A Phase One study with 12 patients would hopefully prove the concept of what is to be developed, the ‘how to’ will inevitably draw on the experiences of PDT with the pancreas, primarily.
The drug used could be the same as with the pancreas (Visudyne) and the method of getting the light to the kidneys would logically adopt the same procedure.
The outcomes for the patient should be really significant, starting with the aim being to ‘manage and control’ the cancer, while hopefully the procedure will be able to destroy a growing number as the treatment is refined.
We hope to update this page shortly, giving you information about the teams being recruited. At that stage, we could open a ring-fenced kidney PDT trial programme.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment